Patients with advanced clear cell renal cell carcinoma (ccRCC) who were treated with the CD70-targeted allogenic chimeric antigen receptor (CAR) T cell therapy, ALLO-316, experienced encouraging results with durable responses, according to results of the Phase 1a/b TRAVERSE clinical trial. This first-in-human study evaluated ALLO-316 in patients with metastatic ccRCC who had progression after treatment with immune checkpoint inhibitors and tyrosine kinase inhibitors. The Phase 1a portion of the study established the recommended dose and lymphodepletion regimen for ALLO-316 while demonstrating a manageable safety profile. In the Phase 1b study, about half of patients saw their cancer stop growing or significantly shrink, with some patients remaining in continued response for over a year after a single infusion of ALLO-316.
“Patients with advanced clear cell renal cell carcinoma who progress on standard therapies have very limited treatment options and historically poor outcomes,” said principal investigator Samer Srour, M.B Ch.B., associate professor of Stem Cell Transplantation and Cellular Therapy. “For years, CAR T cell therapies have transformed outcomes in blood cancers but reproducing that success in solid tumors has proven to be challenging. These results represent an important milestone in expanding the promise of CAR T cell therapy into kidney cancer and other solid tumors.”